Publications by authors named "Yu Kai Tang"
Article Synopsis
- - The study evaluates the cost-effectiveness of combining tislelizumab with gemcitabine plus cisplatin (GP) for treating recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) in China.
- - Using a survival model, it found that this combination therapy resulted in an additional cost of approximately $18,393, yielding 1.57 more quality-adjusted life years (QALYs), with an incremental cost-effectiveness ratio (ICER) of $18,392.75 per QALY.
- - The analysis suggests that tislelizumab plus GP is significantly cost-effective compared to GP alone, with a 99.8% probability of being cost-effective under the willingness-to
Background: Sintilimab combined with IBI305 treatment regimen had potential clinical benefits than sorafenib in the first-line treatment of patients with unresectable hepatic cell carcinoma (HCC). However, whether sintilimab plus IBI305 has economic benefits in China remains unclear.
Methods: From the perspective of Chinese payers, we used the Markov model to simulate patients with HCC receiving treatment with sintilimab plus IBI305 and sorafenib.
Based on the colorectal cancer microarray sets gene expression data series (GSE) GSE10972 and GSE74602 in colon cancer and 222 autophagy-related genes, the differential signature in colorectal cancer and paracancerous tissues was analyzed by RankComp algorithm, and a signature consisting of seven autophagy-related reversal gene pairs with stable relative expression orderings (REOs) was obtained. Scoring based on these gene pairs could significantly distinguish colorectal cancer samples from adjacent noncancerous samples, with an average accuracy of 97.5% in two training sets and 90.
View Article and Find Full Text PDFObjectives: In radiomics, high-throughput algorithms extract objective quantitative features from medical images. In this study, we evaluated CT-based radiomics features, clinical features, in-depth learning features, and a combination of features for predicting a good pathological response (GPR) in non-small cell lung cancer (NSCLC) patients receiving immunotherapy-based neoadjuvant therapy (NAT).
Materials And Methods: We reviewed 62 patients with NSCLC who received surgery after immunotherapy-based NAT and collected clinicopathological data and CT images before and after immunotherapy-based NAT.